Background
Methods
Study design
Adverse and serious advent event reporting
Study outcomes
Statistical analysis
Results
Demographics
Variable | Control/dose escalation (n = 93) | Dose escalation/dose escalation (n = 90) | ||||
---|---|---|---|---|---|---|
CrCL <30 ml/min (n = 14) | CrCL ≥30 to <60 ml/min (n = 31) | CrCL ≥60 ml/min (n = 48) | CrCL <30 ml/min (n = 10) | CrCL ≥30 to <60 ml/min (n = 40) | CrCL ≥60 ml/min (n = 40) | |
Age yearsa
| 68.2 (14.2) | 66.6 (9.3) | 54.8 (11.9) | 66.8 (12.5) | 64.6 (9.6) | 52.5 (12.1) |
Male, n (%) | 7 (50%) | 25 (80.6%) | 46 (95.8) | 9 (90%) | 34 (85%) | 39 (97.5) |
Ethnicity, n (%) | ||||||
NZ European | 6 (42.9%) | 13 (41.9%) | 20 (41.7%) | 2 (20%) | 21 (52.5%) | 14 (35%) |
Maori | 3 (21.4%) | 10 (32.3%) | 9 (18.8%) | 3 (30.0%) | 13 (32.5%) | 13 (32.5%) |
Pacific Island | 4 (28.6%) | 6 (19.4%) | 17 (35.4%) | 5 (50%) | 5 (12.5%) | 9 (22.5%) |
Asian | 1 (7.1) | 2 (6.5%) | 1 (2.1%) | 0 (0%) | 1 (2.5%) | 4 (10.0%) |
Other | 0 (0%) | 0 (0%) | 1 (2.1%) | 0 (0%) | 0 (0%) | 0 (0%) |
Duration of gout (years) | 16.8 (14.8) | 18.2 (14.7) | 18.1 (11.9) | 13.1 (11.2) | 16.9 (11.2) | 16.9 (11.2) |
Baseline serum urate mg/dla
| 8.3 (1.5) | 7.1 (1.6) | 6.8 (1.5) | 8.0 (1.6) | 7.6 (1.6) | 6.5 (1.3) |
CrCL (ml/min) | 19.8 (5.9) | 44.3 (7.9) | 82.4 (16.6 | 21.1 (6.7) | 44.5 (8.1) | 85.5 (17.7) |
Body mass index (kg/m2)a
| 34.6 (7.2) | 35.8 (8.3) | 35.1 (7.5) | 36.9 (8.4) | 35.9 (8.4) | 33.7 (6.8) |
Baseline allopurinol dose mg/dayb
| 135.7 (100-250) | 258.1 (150-400) | 328.1 (200-600) | 160.0 (100-300) | 231.9 (100-600) | 317.5 (150-600) |
Allopurinol dose, n (%) | ||||||
≤ 200 mg/day | 13 (92.9%) | 13 (41.9%) | 5 (10.4%) | 9 (90%) | 25 (62.5%) | 3 (7.5%) |
> 200–300 mg/day | 1 (7.1%) | 16 (51.6%) | 33 (68.8%) | 1 (10%) | 13 (32.5%) | 32 (80%) |
> 300 mg/day | 0 (0%) | 2 (6.5%) | 10 (20.8%) | 0 (0%) | 2 (5%) | 7 (7.8%) |
Presence of palpable tophi, n (%) | 10 (71.4%) | 14 (45.2%) | 22 (45.8%) | 4 (40%) | 13 (32.5%) | 18 (45%) |
Co-existing conditions, n (%) | ||||||
Obesityc
| 11 (78.6%) | 23 (74.2%) | 36 (75%) | 8 (80%) | 29 (72.5%) | 27 (67.5%) |
Kidney stones | 0 (0%) | 1 (3.2%) | 2 (4.2%) | 1 (10%) | 3 (7.5%) | 1 (2.5%) |
Cardiovascular diseased
| 13 (92.9%) | 14 (45.2%) | 11 (22.9%) | 5 (50%) | 26 (65%) | 10 (25%) |
Diabetes mellitus | 8 (57.1%) | 12 (38.7%) | 13 (27.1%) | 7 (70%) | 18 (45%) | 4 (10%) |
Hypertension | 11 (78.6%) | 29 (93.5%) | 25 (52.1%) | 9 (90%) | 36 (90%) | 22 (55%) |
Hyperlipidemia | 12 (85.7%) | 19 (61.3%) | 27 (56.3%) | 7 (70%) | 22 (55%) | 18 (45%) |
Concurrent medications, n (%) | ||||||
Diuretic | 13 (92.9) | 19 (61.3%) | 11 (22.9%) | 7 (70%) | 23 (57.5%) | 8 (20.0%) |
Aspirin | 11 (78.6%) | 17 (54.8%) | 13 (27.1%) | 7 (70%) | 23 (57.5%) | 10 (25%) |
Any anti-inflammatory prophylaxis | 5 (35.7%) | 15 (48.4%) | 25 (52.1%) | 4 (40%) | 24 (60%) | 23 (57.5%) |
Colchicine | 2 (14.3%) | 11 (25.5%) | 22 (45.8%) | 3 (30%) | 13 (32.5%) | 18 (45%) |
NSAID | 0 (0%) | 3 (9.7%) | 6 (12.5%) | 2 (20%) | 4 (10%) | 9 (22.5%) |
Prednisone | 3 (21.4%) | 8 (19.4%) | 3 (6.3%) | 1 (10%) | 9 (22.5%) | 2 (5%) |
Serum urate
Variable | C/DE (n = 93) | DE/DE (n = 90) |
P valuesa
| ||||
---|---|---|---|---|---|---|---|
CrCL <30 ml/min (n = 14) | CrCL ≥30 to <60 ml/min (n = 31) | CrCL ≥60 ml/min (n = 48) | CrCL <30 ml/min (n = 10) | CrCL ≥30 to<60 ml/min (n = 40) | CrCL ≥60 ml/min (n = 40) | ||
Change in serum urate (mg/dl), mean (SE) | |||||||
Baseline to month 12 | -0.67 (0.67) | -0.05 (0.33) | -0.25 (0.26) | -1.49 (0.47) | -2.27 (0.29) | -1.06 (0.24) | 0.04 |
Baseline to month 24 | -2.23 (0.88) | -1.41 (0.36) | -1.10 (0.25) | -2.47 (0.68) | -2.35 (0.28) | -0.86 (0.27) | 0.15 |
Month 12 to month 24 | -1.42 (0.45) | -1.51 (0.41) | -0.87 (0.25) | -1.20 (0.29) | 0.01 (0.17) | 0.34 (0.23) | 0.82 |
Serum urate <6 mg/dl, % | |||||||
Month 12 | 13% | 25% | 49% | 57% | 86% | 86% | 0.50 |
Month 24 | 57% | 68% | 72% | 71% | 82% | 79% | 0.93 |
Mean (SE) serum urate | |||||||
Baseline | 8.25 (0.41) | 7.10 (0.29) | 6.82 (0.21) | 8.02 (0.46) | 7.63 (0.26) | 6.52 (0.20) | <0.001b
|
Month 12 | 7.38 (0.57) | 7.13 (0.32) | 6.37 (0.24) | 5.91 (0.59) | 5.25 (0.12) | 5.34 (0.19) | 0.20 |
Month 24 | 5.93 (0.71) | 5.72 (0.25) | 5.62 (0.19) | 5.21 (0.30) | 5.27 (0.18) | 5.61 (0.25) | 0.46 |
Percentage change in serum urate from baseline, mean (SE) | |||||||
Baseline to month 12 | -6.2 (7.2) | 1.6 (4.9) | -1.9 (3.4) | -20.2 (6.0) | -27.5 (2.9) | -15.0 (3.5) | 0.08 |
Baseline to month 24 | -25.5 (8.5) | -16.6 (4.8) | -13.9 (3.2) | -30.0 (5.8) | -29.1 (2.8) | -11.8 (4.1) | 0.14 |
Month 12 to month 24 | -19.4 (5.4) | -17.9 (4.6) | -10.1 (3.5) | -2.4 (5.4) | 0.87 (3.2) | 7.75 (4.6) | 0.99 |
Percentage with at least one flare in preceding month | |||||||
Baseline | 50% | 38.7% | 56.3% | 40.0% | 32.5% | 42.5% | 0.17b
|
Month 12 | 37.5% | 12.5% | 39% | 14.3% | 34.3% | 32.1% | 0.10 |
Month 24 | 14.3% | 13.6% | 20.5% | 0.0% | 15.2% | 3.4% | 0.30 |
Allopurinol dose (mg/day) to achieve target SU at month 24, mean (range) | 262.5 (150–500) | 389.3 (250–650) | 439.3 (300–800) | 350.0 (250–600) | 396.3 (200–700) | 491.3 (300–900) | 0.002b
|
Number of participants requiring >300 mg/day to achieve target SU at month 24 | 1/4 (25%) | 9/14 (64.3%) | 20/28 (71.4%) | 1/5 (20%) | 16/27 (59.3%) | 19/23 (82.6%) | 0.013 |
Percentage of individuals receiving anti-inflammatory prophylaxis | |||||||
Baseline | 35.7% | 48.4% | 52.1% | 40.0% | 60.0% | 57.5% | 0.30b
|
Month 12 | 37.5% | 29.2% | 29.3% | 71.4% | 34.3% | 14.3% | 0.15 |
Month 24 | 14.3% | 18.2% | 15.4% | 57.1% | 9.1% | 10.3% | 0.16 |
HAQ mean (SE) change | |||||||
Baseline to month 12 | -0.10 (0.19) | 0.10 (0.15) | -0.14 (0.09) | 0.47 (0.28) | 0.06 (0.12) | -0.13 (0.11) | 0.25 |
Baseline to month 24 | -0.09 (0.21) | 0.14 (0.11) | -0.32 (0.07) | -0.19 (0.30) | -0.05 (0.11) | -0.20 (0.12) | 0.67 |
Month 12 to month 24 | 0.10 (0.04) | -0.09 (0.18) | -0.22 (0.08) | -0.72 (0.35) | -0.05 (0.13) | -0.05 (0.11) | 0.04 |
Pain VAS mean (SE) change | |||||||
Baseline to month 12 | -0.25 (0.90) | 1.04 (0.51) | -0.02 (0.40) | 0.43 (0.61) | 0.17 (0.40) | -0.43 (0.54) | 0.57 |
Baseline to month 24 | -1.15 (1.3) | 0.27 (0.62) | -1.10 (0.35) | -0.50 (1.36) | -0.64 (0.37) | -1.28 (0.53) | 0.56 |
Month 12 to month 24 | -0.71 (0.71) | -0.52 (0.84) | -1.03 (0.37) | -0.60 (0.87) | -0.67 (0.34) | -0.78 (0.57) | 0.93 |
SJC mean (SE) change | |||||||
Baseline to month 12 | -2.88 (1.84) | -0.04 (1.05) | -0.07 (0.72) | 0.86 (1.6) | -1.17 (0.89) | 0.17 (0.53) | 0.19 |
Baseline to month 24 | -2.14 (1.39) | -2.86 (1.65) | -1.26 (0.73) | -0.67 (0.67) | -1.85 (0.93) | -0.24 (0.27) | 0.99 |
Month 12 to month 24 | 1.23 (1.16) | -2.91 (2.24) | -1.34 (0.98) | 0 (0) | -0.52 (0.42) | -0.37 (0.59) | 0.57 |
TJC mean (SE) change | |||||||
Baseline to month 12 | 2.13 (3.56) | 0.04 (1.33) | -2.83 (1.07) | -0.57 (0.62) | -1.57 (0.90) | 1.18 (1.42) | 0.04 |
Baseline to month 24 | -2.57 (1.97) | -1.73 (1.49) | -2.08 (0.88) | -0.50 (0.34) | -0.42 (1.54) | -0.97 (0.50) | 0.97 |
Month 12 to month 24 | -5.0 (3.0) | -2.57 (1.83) | 0.65 (0.55) | -0.20 (0.20) | 1.18 (1.32) | -1.96 (1.37) | 0.02 |
Allopurinol dose
Adverse events
CTCAE category | Time period | Control (n = 93) | Dose escalation (n = 90) | ||||
---|---|---|---|---|---|---|---|
CrCL <30 ml/min (n = 14) | CrCL ≥30 to <60 ml/min (n = 31) | CrCL ≥60 ml/min (n = 48) | CrCL <30 ml/min (n = 10) | CrCL ≥30 to <60 ml/min (n = 40) | CrCL ≥60 ml/min (n = 40) | ||
Cardiac disorders | Month 0–12 | 6 (3) | 7 (4) | 1 (1) | 1 (1) | 9 (7) | 4 (3) |
Month 13–24 | 3 (2) | 8 (5) | 0 | 0 | 6 (5) | 2 (2) | |
Gastrointestinal disorders | Month 0–12 | 1 (1) | 3 (3) | 2 (2) | 0 | 3 (3) | 0 |
Month 13–24 | 0 | 5 (4) | 1 (1) | 0 | 3 (3) | 0 | |
General disorders | Month 0–12 | 1 (1) | 0 | 0 | 0 | 0 | 1 (1) |
Month 13–24 | 1 (1) | 0 | 1 (1) | 0 | 0 | 1 (1) | |
Hepatobiliary disorders | Month 0–12 | 0 | 0 | 0 | 0 | 1 (1) | 0 |
Month 13–24 | 0 | 0 | 0 | 0 | 0 | 0 | |
Infections and infestations | Month 0–12 | 2 (2) | 3 (3) | 3 (3) | 1 (1) | 2 (1) | 1 (1) |
Month 13–24 | 0 | 6 (4) | 2 (2) | 3 (3) | 5 (3) | 1 (1) | |
Injury, poisoning and procedural complications | Month 0–12 | 1 (1) | 0 | 1 (1) | 0 | 1 (1) | 0 |
Month 13–24 | 1 (1) | 3 (2) | 1 (1) | 0 | 1 (1) | 0 | |
Investigations | Month 0–12 | 0 | 0 | 0 | 0 | 1 (1) | 0 |
Month 13–24 | 0 | 0 | 0 | 0 | 0 | 0 | |
Metabolism and nutrition | Month 0–12 | 0 | 0 | 0 | 1 (1) | 1 (1) | 0 |
Month 13–24 | 0 | 0 | 0 | 0 | 0 | 0 | |
Musculoskeletal | Month 0–12 | 0 | 0 | 1 (1) | 1 (1) | 0 | 0 |
Month 13–24 | 0 | 0 | 2 (1) | 0 | 1 (1) | 0 | |
Nervous system disorders | Month 0–12 | 1 (1) | 1 (1) | 1 (1) | 0 | 0 | 1 (1) |
Month 13–24 | 3 (2) | 0 | 0 | 1 (1) | 3 (3) | 0 | |
Renal and urinary disorders | Month 0–12 | 3 (3) | 2 (2) | 0 | 1 (1) | 1 (1) | 0 |
Month 13–24 | 0 | 0 | 0 | 2 (2) | 1 (1) | 0 | |
Respiratory, thoracic and mediastinal disorders | Month 0–12 | 0 | 1 (1) | 1 (1) | 1 (1) | 1 (1) | 0 |
Month 13–24 | 0 | 0 | 0 | 0 | 0 | 0 | |
Skin and subcutaneous tissue disorders | Month 0–12 | 1 (1) | 0 | 0 | 0 | 0 | 2 (1) |
Month 13–24 | 0 | 0 | 0 | 0 | 0 | 0 | |
Psychiatric disorders | Month 0–12 | 0 | 0 | 0 | 0 | 0 | 0 |
Month 13–24 | 1 (1) | 0 | 0 | 0 | 0 | 1 (1) | |
Vascular disorders | Month 0–12 | 0 | 0 | 0 | 0 | 0 | 0 |
Month 13–24 | 0 | 0 | 0 | 0 | 1 (1) | 0 |